H.R. 6257 (109th): Access to Life-Saving Medicine Act

Sep 29, 2006 (109th Congress, 2005–2006)
Died (Referred to Committee)
Henry Waxman
Representative for California's 30th congressional district
Read Text »
Last Updated
Sep 29, 2006
39 pages
Related Bills
S. 4016 (Related)
Access to Life-Saving Medicine Act

Referred to Committee
Last Action: Sep 29, 2006


This bill was introduced on September 29, 2006, in a previous session of Congress, but was not enacted.

Introduced Sep 29, 2006
Referred to Committee Sep 29, 2006
Full Title

To amend the Public Health Service Act to provide for the licensing of comparable biological products, and for other purposes.


No summaries available.

1 cosponsors (1D) (show)

House Energy and Commerce


House Judiciary

House Ways and Means

The committee chair determines whether a bill will move past the committee stage.

Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.


Get a bill status widget for your website »


Click a format for a citation suggestion:


H.R. stands for House of Representatives bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.

Access to Life-Saving Medicine Act - Amends the Public Health Service Act to establish a process for the approval of a comparable biological product based on its similarity to a previously licensed biological product (the reference product).
Allows a person to file an abbreviated comparable product application with the Secretary of Health and Human Services that includes:
(1) data demonstrating that the product is comparable to the reference product;
(2) information to show that the conditions or conditions of use prescribed, recommended, or suggested in the labeling proposed for the comparable product have been previously approved for the reference product; and
(3) information to show that the route of administration, the dosage form, and the strength of the comparable product are the same as those of the reference product.
Sets forth conditions for approval of such an application by the Secretary.
Allows an applicant to request that the Secretary make a determination as to the interchangeability of a comparable product and the reference product. Provides market exclusivity to such an interchangeable product.
Requires the Secretary to establish requirements for the efficient review, approval, suspension, and revocation of comparable product applications.
Sets forth provisions governing patent infringement claims against the license holder of a comparable product.
Amends the Internal Review Code to allow a tax credit for qualified clinical testing expenses.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.

No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of H.R. 6257 (109th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus